Evidence map›Paper›PMID 40459937›Full record

ArticleThe Journal of clinical investigation2025

Mutant THAP11 causes cerebellar neurodegeneration and triggers TREM2-mediated microglial activation in mice.

Eshu Ruan, Jingpan Lin, Zhao Chen, Qianai Sheng, Laiqiang Chen, Jiating He, Xuezhi Duan, Yiyang Qin, Tingting Xing, Sitong Yang and 7 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. From Thanatos to transcription: the emerging biology of THAP proteins.Cellular and molecular life sciences : CMLS · 2026
    Review
  2. Cells · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Eshu RuanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Jingpan LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Zhao ChenDepartment of Neurology, Xiangya Hospital.
Qianai ShengState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Laiqiang ChenState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Jiating HeState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Xuezhi DuanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Yiyang QinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Tingting XingState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Sitong YangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Mingtian PanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Xiangyu GuoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Peng YinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Xiao-Jiang LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Hong JiangDepartment of Neurology, Xiangya Hospital.
Shihua LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.
Su YangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormal expansions of the CAG trinucleotide repeat within specific gene exons give rise to polyglutamine (polyQ) diseases, a family of inherited disorders characterized by late-onset neurodegeneration. Recently, a new type of polyQ disease was identified and named spinocerebellar ataxia 51 (SCA51). SCA51 is caused by polyQ expansion in THAP domain containing 11 (THAP11), an essential transcription factor for brain development. The pathogenesis of SCA51, particularly how mutant THAP11 with polyQ expansion contributes to neuropathology, remains elusive. Our study of mouse and monkey brains revealed that THAP11 expression is subject to developmental regulation, showing enrichment in the cerebellum. However, knocking down endogenous THAP11 in adult mice did not affect neuronal survival. In contrast, expressing mutant THAP11 with polyQ expansion led to pronounced protein aggregation, cerebellar neurodegeneration, and motor deficits, indicating that gain-of-function mechanisms are central to SCA51 pathogenesis. We discovered activated microglia expressing triggering receptor expressed on myeloid cells 2 (TREM2) in the cerebellum of a newly developed SCA51 knockin mouse model. Mechanistically, mutant THAP11 enhanced the transcription of TREM2, leading to its upregulation. The loss of TREM2 or depletion of microglia mitigated neurodegeneration induced by mutant THAP11. Our study offers the first mechanistic insights to our knowledge into the pathogenesis of SCA51, highlighting the role of TREM2-mediated microglial activation in SCA51 neuropathology.

Indexed as

CerebellumDNA-Binding ProteinsMembrane GlycoproteinsMicrogliaMutationReceptors, ImmunologicRepressor ProteinsSpinocerebellar AtaxiasAnimalsDisease Models, AnimalHumansMiceMice, TransgenicDNA-Binding ProteinsMembrane GlycoproteinsReceptors, ImmunologicRepressor ProteinsTrem2 protein, mouseGeneticsMouse modelsNeurodegenerationNeuroscienceProtein misfolding

Identifiers

PMID40459937
PMCPMC12259261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.